Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | NAMPT | P43490 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95759 | 0.86 | NAMPT (0.61) | MAPTHTTNAMPTSLC6A7ALDH1A1 | |
| SCHEMBL17886718 | 0.86 | ALDH1A1 (0.59) | MAPTHTTNAMPTLMNAKDM4E | |
| SCHEMBL12082812 | 0.83 | LMNA (0.69) | MAPTHTTNAMPTLMNASLC6A7 | |
| SCHEMBL2377185 | 0.83 | ALDH1A1 (0.57) | MAPTHTTNAMPTLMNAALDH1A1 | |
| SCHEMBL10721885 | 0.83 | POLB (0.74) | MAPTLMNASLC6A7KDM4EALDH1A1 | |
| SCHEMBL1433477 | 0.80 | TRPV1 (0.54) | MAPTNAMPTALDH1A1 | |
| SCHEMBL30663952 | 0.80 | TRPV1 (0.54) | MAPTNAMPTALDH1A1 | |
| SCHEMBL27781454 | 0.79 | TRPV1 (0.56) | NAMPTALDH1A1 | |
| SCHEMBL21987023 | 0.79 | MAPT (0.69) | MAPTHTTNAMPTLMNASLC6A7 | |
| SCHEMBL22495238 | 0.79 | MAPT (0.74) | MAPTHTTNAMPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | MAPT 2732/4885HTT 4749/4885NAMPT 1885/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | MAPT 2732/4885HTT 4749/4885NAMPT 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.